Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

A review of Eplontersen use in hereditary transthyretin amyloidosis.

A review of Eplontersen use in hereditary transthyretin amyloidosis.

Journal: Neurodegenerative disease management
Published: August 30, 2025

Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going.

Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going.

Journal: Journal of clinical medicine
Published: April 19, 2025

Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.

Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.

Journal: Journal of neurology
Published: February 03, 2025

Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation.

Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation.

Journal: Kardiologia polska
Published: December 13, 2024

Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial.

Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: November 18, 2024

Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications.

Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications.

Journal: Pharmacotherapy
Published: September 30, 2024

Hope on the horizon: FDA approves eplontersen for hereditary transthyretin-mediated amyloidosis.

Hope on the horizon: FDA approves eplontersen for hereditary transthyretin-mediated amyloidosis.

Journal: Annals of medicine and surgery (2012)
Published: July 05, 2024

A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.

A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.

Journal: Medicine
Published: June 28, 2024

Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.

Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.

Journal: Journal of neurology
Published: June 27, 2024

RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions.

RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions.

Journal: Cureus
Published: June 23, 2024

Eplontersen Sodium.

Eplontersen Sodium.

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: June 09, 2024

Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.

Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: June 04, 2024
Showing 1-12 of 31

Last Updated: 10/31/2025